Topics

Purpose The NINDS is committed to advancing treatments for people burdened by the neurological disorders that fall under the NINDS mission. Traditionally, large pharmaceutical and biotechnology companies, as well as venture capital firms, have provided the resources needed to conduct the clinical studies required to fully develop and commercialize biomedical products and technologies. More rece ...

Animal models are essential for research, contributing to the understanding of the pathobiology of human diseases and facilitating the development of diagnostic approaches and therapeutic interventions. A large number of animal genetic stocks, including models of human diseases, have been generated at an unprecedented fast pace due to rapidly evolving gene editing technologies. However, this rapid ...

Animal models are essential for research, contributing to the understanding of the pathobiology of human diseases and facilitating the development of diagnostic approaches and therapeutic interventions. A large number of animal genetic stocks, including models of human diseases, have been generated at an unprecedented fast pace due to rapidly evolving gene editing technologies. However, this rapid ...

Purpose NINDS is committed to advancing diagnostics and treatments for people burdened by neurological diseases and the NINDS Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs have provided the small business community with critical seed funding to support the development of a wide variety of technologies and therapeutics for the diagnosis and trea ...

Purpose This Funding Opportunity Announcement (FOA) encourages grant applications from SBCs to develop or adapt, apply, and validate existing or emerging technologies into user-friendly, low-resource setting-appropriate technologies for cancer prevention, diagnosis, or treatment. Projects proposed for this FOA will require multidisciplinary efforts to succeed, and, therefore, all app ...

Purpose This Funding Opportunity Announcement (FOA) encourages grant applications from SBCs to develop or adapt, apply, and validate existing or emerging technologies into user-friendly, low-resource setting-appropriate technologies for cancer prevention, diagnosis, or treatment. Projects proposed for this FOA will require multidisciplinary efforts to succeed, and, therefore, all app ...

The NIH and other research sponsors invest a significant amount of funds in the development of new technologies to study the brain and behavior, from basic and clinical perspectives, through a variety of mechanisms, including, from NIH, the R01, R21, R33, P01, P41, and P50 grants. This investment has produced a large number of technologies that include hardware (e.g., instruments, devices, etc.), ...

This Funding Opportunity Announcement (FOA) seeks small business grant applications to develop major advances in genomic technologies. Advances in basic research, clinical applications of genomics and more broadly in biomedical research have been greatly facilitated by significant and sustained genomics technology throughput increases, cost decreases, and improvements in ease of use. The prop ...

Purpose This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials. A clinical trial is defined by NIH as: "A research study in which one or more human subjects are prospectively assigned to one or more interventions  ...

The SBIR Technology Transfer (SBIR-TT) Funding Opportunity Announcement (FOA) is intended to help move commercially-viable technologies from the NIH Intramural Program to the marketplace. Small Business Concerns (SBCs) are encouraged to submit applications that further develop available technologies from the NIH Intramural Program and bring them to the commercial market. While universities can spi ...